hypoparathyrodism

The drug, which was previously approved for osteoporosis treatment in Europe from 2006 to 2013, met the primary endpoints of decreased need for vitamin D and calcium in patients with hypoparathyroidism, as was shown by the manufacturer in their pivotal trial. “A once-a-day injection provided a...